Table 3.

Univariate associations between clinical benefit and PFS on anti-EGFR-based clinical trial retreatment

Patient characteristics	Clinical benefit			PFS
	Total (n)	Responded n (%)	p	Total (n)	Progressed (n)	Median (95 % CI)	p
Response to prior anti-EGFR treatment
No	50	23 (46)	0.007	52	45	2.50 (1.58, 3.42)	0.064
Yes	36	27 (75)		37	31	4.90 (3.60, 6.20)
Interval length between treatments
< median	42	20 (48)	0.053	44	40	3.20 (1.97, 4.43)	0.286
≥ median	44	30 (68)		45	36	4.10 (2.61, 5.59)
Race/Ethnicity
Non-White	24	17(71)	0.138	26	22	5.20 (3.94, 6.46)	0.034
White	62	33(53)		63	54	3.00 (1.92, 4.08)
Gender
Female	43	24 (56)	0.662	44	41	3.80 (2.88, 4.72)	0.323
Male	43	26 (61)		45	35	3.70 (2.48, 4.92)
Age
< 60 years	55	32 (58)	0.992	57	50	3.70 (2.91, 4.49)	0.619
≥ 60 years	31	18 (58)		32	26	3.80 (2.03, 5.57)
PS (ECOG)
0	32	20 (63)	0.528	35	28	3.80 (2.67, 4.93)	0.286
≥ 1	54	30 (56)		54	48	3.60 (2.08, 5.12)
Number of metastatic sites
< 3	42	26 (62)	0.489	42	35	4.50 (3.03, 5.97)	0.077
≥ 3	44	24 (55)		47	41	3.20 (1.92, 4.48)
Serum albumin
Normal	69	40 (58)	0.949	72	61	3.80 (3.18, 4.42)	0.920
Low	17	10 (59)		17	15	3.00 (0.00, 6.77)
Serum LDH
Normal	19	9 (47)	0.281	19	15	2.80 (0.37, 5.24)	0.667
Elevated	67	41(61)		70	61	3.80 (3.05, 4.55)
RMH score
0 or 1	43	25 (58)	1.000	43	35	3.70 (2.00, 5.40)	0.408
2 or 3	43	25 (58)		46	41	3.80 (2.81, 4.79)